263 related articles for article (PubMed ID: 20339976)
1. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
[TBL] [Abstract][Full Text] [Related]
2. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
[TBL] [Abstract][Full Text] [Related]
3. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Gupta V; Gupta N; Shaik IH; Mehvar R; McMurtry IF; Oka M; Nozik-Grayck E; Komatsu M; Ahsan F
J Control Release; 2013 Apr; 167(2):189-99. PubMed ID: 23353807
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
[TBL] [Abstract][Full Text] [Related]
5. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Ruan H; Zhang Y; Liu R; Yang X
Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
Fukumoto Y; Yamada N; Matsubara H; Mizoguchi M; Uchino K; Yao A; Kihara Y; Kawano M; Watanabe H; Takeda Y; Adachi T; Osanai S; Tanabe N; Inoue T; Kubo A; Ota Y; Fukuda K; Nakano T; Shimokawa H
Circ J; 2013; 77(10):2619-25. PubMed ID: 23912836
[TBL] [Abstract][Full Text] [Related]
7. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
Jiang X; Wang YF; Zhao QH; Jiang R; Wu Y; Peng FH; Xu XQ; Wang L; He J; Jing ZC
Int J Cardiol; 2014 Nov; 177(1):61-5. PubMed ID: 25499341
[TBL] [Abstract][Full Text] [Related]
8. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Nagaoka T; Fagan KA; Gebb SA; Morris KG; Suzuki T; Shimokawa H; McMurtry IF; Oka M
Am J Respir Crit Care Med; 2005 Mar; 171(5):494-9. PubMed ID: 15563635
[TBL] [Abstract][Full Text] [Related]
9. CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil.
Keshavarz A; Alobaida A; McMurtry IF; Nozik-Grayck E; Stenmark KR; Ahsan F
Mol Pharm; 2019 Aug; 16(8):3414-3429. PubMed ID: 31194563
[TBL] [Abstract][Full Text] [Related]
10. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
Ishikura K; Yamada N; Ito M; Ota S; Nakamura M; Isaka N; Nakano T
Circ J; 2006 Feb; 70(2):174-8. PubMed ID: 16434811
[TBL] [Abstract][Full Text] [Related]
11. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
Fukumoto Y; Matoba T; Ito A; Tanaka H; Kishi T; Hayashidani S; Abe K; Takeshita A; Shimokawa H
Heart; 2005 Mar; 91(3):391-2. PubMed ID: 15710736
[No Abstract] [Full Text] [Related]
12. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Badejo AM; Dhaliwal JS; Casey DB; Gallen TB; Greco AJ; Kadowitz PJ
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L828-36. PubMed ID: 18689606
[TBL] [Abstract][Full Text] [Related]
13. Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
Rashid J; Nahar K; Raut S; Keshavarz A; Ahsan F
Mol Pharm; 2018 May; 15(5):1755-1765. PubMed ID: 29528655
[TBL] [Abstract][Full Text] [Related]
14. Fasudil inhibits the myogenic response in the fetal pulmonary circulation.
Tourneux P; Chester M; Grover T; Abman SH
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1505-13. PubMed ID: 18676688
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Oka M; Homma N; Taraseviciene-Stewart L; Morris KG; Kraskauskas D; Burns N; Voelkel NF; McMurtry IF
Circ Res; 2007 Mar; 100(6):923-9. PubMed ID: 17332430
[TBL] [Abstract][Full Text] [Related]
16. Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
Schinzari F; Tesauro M; Rovella V; Di Daniele N; Gentileschi P; Mores N; Campia U; Cardillo C
Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E806-11. PubMed ID: 22829585
[TBL] [Abstract][Full Text] [Related]
17. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Li F; Xia W; Yuan S; Sun R
Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
[TBL] [Abstract][Full Text] [Related]
18. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Raja SG
Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
[TBL] [Abstract][Full Text] [Related]
20. Effects of fasudil on pulmonary hypertension in clinical practice.
Zhang Y; Wu S
Pulm Pharmacol Ther; 2017 Oct; 46():54-63. PubMed ID: 28782712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
